These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35565337)

  • 1. A Tumor-Homing Peptide Platform Enhances Drug Solubility, Improves Blood-Brain Barrier Permeability and Targets Glioblastoma.
    Cho CF; Farquhar CE; Fadzen CM; Scott B; Zhuang P; von Spreckelsen N; Loas A; Hartrampf N; Pentelute BL; Lawler SE
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting glioblastoma using a novel peptide specific to a deglycosylated isoform of brevican.
    von Spreckelsen N; Fadzen CM; Hartrampf N; Ghotmi Y; Wolfe JM; Dubey S; Yang BY; Kijewski MF; Wang S; Farquhar C; Bergmann S; Zdioruk M; Wasserburg JR; Scott B; Murrell E; Bononi FC; Luyt LG; DiCarli M; Lamfers MLM; Ligon KL; Chiocca EA; Viapiano MS; Pentelute BL; Lawler SE; Cho CF
    Adv Ther (Weinh); 2021 Apr; 4(4):. PubMed ID: 33997269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Prodrug of Camptothecin for Enhanced Treatment of Glioblastoma Multiforme.
    Checa-Chavarria E; Rivero-Buceta E; Sanchez Martos MA; Martinez Navarrete G; Soto-Sánchez C; Botella P; Fernández E
    Mol Pharm; 2021 Apr; 18(4):1558-1572. PubMed ID: 33645231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of axitinib regulating the pathological blood-brain barrier functional recovery for glioblastoma therapeutics.
    Zhang F; Wen L; Wang K; Huang Z; Jin X; Xiong R; He S; Hu F
    CNS Neurosci Ther; 2022 Mar; 28(3):411-421. PubMed ID: 34967104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy.
    Zhou W; Chen C; Shi Y; Wu Q; Gimple RC; Fang X; Huang Z; Zhai K; Ke SQ; Ping YF; Feng H; Rich JN; Yu JS; Bao S; Bian XW
    Cell Stem Cell; 2017 Nov; 21(5):591-603.e4. PubMed ID: 29100012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.
    Kim M; Ma DJ; Calligaris D; Zhang S; Feathers RW; Vaubel RA; Meaux I; Mladek AC; Parrish KE; Jin F; Barriere C; Debussche L; Watters J; Tian S; Decker PA; Eckel-Passow JE; Kitange GJ; Johnson AJ; Parney IF; Anastasiadis PZ; Agar NYR; Elmquist WF; Sarkaria JN
    Mol Cancer Ther; 2018 Sep; 17(9):1893-1901. PubMed ID: 29970480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A narrative review of research progress on drug therapies for glioblastoma multiforme.
    Zheng X; Tang Q; Ren L; Liu J; Li W; Fu W; Wang J; Du G
    Ann Transl Med; 2021 Jun; 9(11):943. PubMed ID: 34350258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles.
    Norouzi M; Yathindranath V; Thliveris JA; Kopec BM; Siahaan TJ; Miller DW
    Sci Rep; 2020 Jul; 10(1):11292. PubMed ID: 32647151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF-mediated tight junctions pathological fenestration enhances doxorubicin-loaded glycolipid-like nanoparticles traversing BBB for glioblastoma-targeting therapy.
    Wen L; Tan Y; Dai S; Zhu Y; Meng T; Yang X; Liu Y; Liu X; Yuan H; Hu F
    Drug Deliv; 2017 Nov; 24(1):1843-1855. PubMed ID: 29182025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.
    Sarkaria JN; Hu LS; Parney IF; Pafundi DH; Brinkmann DH; Laack NN; Giannini C; Burns TC; Kizilbash SH; Laramy JK; Swanson KR; Kaufmann TJ; Brown PD; Agar NYR; Galanis E; Buckner JC; Elmquist WF
    Neuro Oncol; 2018 Jan; 20(2):184-191. PubMed ID: 29016900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facile synthesis of lactoferrin conjugated ultra small large pore silica nanoparticles for the treatment of glioblastoma.
    Janjua TI; Ahmed-Cox A; Meka AK; Mansfeld FM; Forgham H; Ignacio RMC; Cao Y; McCarroll JA; Mazzieri R; Kavallaris M; Popat A
    Nanoscale; 2021 Oct; 13(40):16909-16922. PubMed ID: 34533167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
    Wang D; Wang C; Wang L; Chen Y
    Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
    Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
    Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
    Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Challenges and Opportunities in Treating Glioblastoma.
    Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N
    Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomaterials and 3D Bioprinting Strategies to Model Glioblastoma and the Blood-Brain Barrier.
    Tang M; Rich JN; Chen S
    Adv Mater; 2021 Feb; 33(5):e2004776. PubMed ID: 33326131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
    Gutkin A; Cohen ZR; Peer D
    Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.